Q3 2026 earnings call likely delivered first hard test of DTC-driven acceleration; details remain thin.

What happened

The Q3 2026 earnings call on October 29 provided the first full-quarter read after the January DTC launch, but the truncated transcript leaves key financials unverified. Management probably reported net product revenue and prescription trends, but without explicit figures, investors cannot confirm whether the ramp exceeded the Q4 2025 baseline of $1.6M revenue and 20,000 prescriptions. The DeepValue master report set a hurdle of sequential acceleration to $3-5M quarterly revenue by mid-2026; missing that would signal the 88-territory sales force and DTC spend are not converting to demand. Given the company's prior pattern of selective disclosure, the call may have emphasized positive prescription growth while obscuring weak revenue or persistence. The critical question is whether repeat prescriber behavior stayed above 50% and whether cash burn remains manageable against the $188.9M liquidity position.

Implication

The Q3 call was a pivotal checkpoint: if the company disclosed only vague prescription counts without net revenue figures, the thesis weakens because DTC spend may be generating low-value trial rather than durable demand. A failure to show sequential acceleration versus Q2 2026 would push the equity toward the bear case of $7, while a clear step-up to $5M+ would support the base case of $14. Cash burn remains the swing factor, and any signal of upcoming financing would amplify downside given the fragile sentiment around the retinal safety label. Until concrete numbers emerge, maintain a small position and treat any management commentary about 'strong prescriber adoption' with skepticism. The next 90-day window will be critical to see if the company provides updated prescription data or if the information vacuum persists.

Thesis delta

The thesis is now under stress; the Q3 call was expected to validate DTC-driven acceleration, but the lack of verified financials prevents confirmation. If net product revenue did not at least double from Q4 2025 baseline, the bear case becomes more likely. The burden is on management to disclose sequential revenue growth, not just prescription volume, to sustain the buy rating.